SOURCE: Entelos, Inc.

January 17, 2007 15:32 ET

American Diabetes Association and Entelos Announce In Silico Research Funding Opportunity

Diabetes Research Center to Apply Biosimulation to Support Type 1 Diabetes Research

ALEXANDRIA, VA and FOSTER CITY, CA -- (MARKET WIRE) -- January 17, 2007 -- The American Diabetes Association (ADA) and Entelos, Inc. (LSE: ENTL) announced today a funding opportunity to support basic research through the Diabetes Research Center (DRC), a joint initiative of the ADA and Entelos to enhance the understanding of diabetes and its treatment. Awardees will have access to the DRC's in silico modeling and biosimulation capabilities, allowing them an unparalleled ability to investigate the onset, progression, and treatment of diabetes.

The ADA and Entelos collaborated to develop the Type 1 Diabetes PhysioLab® platform, a computer-based mathematical model of the non-obese diabetic (NOD) mouse, the primary animal model used to study type 1 diabetes. Research using the platform allows scientists to explore, for example, (1) the contribution of key cell types to disease pathogenesis and prevention, (2) the time- and dose-dependent effects of treatments on disease prevention or remission, and (3) different experimental approaches to identify the most productive research opportunities.

"The ADA is committed to finding new treatments and, ultimately, a cure for diabetes, in particular, type 1 diabetes, which primarily affects children and young adults," said Richard Kahn, Ph.D., chief scientific and medical officer, American Diabetes Association. "This funding opportunity achieves a major goal of the ADA, namely, to apply cutting-edge science to basic diabetes research. By combining the DRC's capabilities with the experimental capabilities of academic researchers, we hope that this initiative will accelerate understanding of the disease."

"With the availability of this research platform, academic researchers will for the first time be able to combine the benefits of in silico research with their own laboratory investigations," added Mikhail Gishizky, Ph.D., chief scientific officer of Entelos. "In fact, this combined approach has already uncovered insights regarding the pathophysiology of type 1 diabetes. Ultimately, this information will improve the rationale for taking novel interventions into humans."

The DRC is soliciting letters of intent (LOI) for in silico research projects to be conducted in the second half of 2007. LOI's will be reviewed by an ADA-sponsored scientific review committee. Applicable projects will be selected, and researchers will be invited to develop a detailed research plan in collaboration with DRC staff. The review committee will then award research grants.

Details regarding the DRC, the Type 1 Diabetes PhysioLab platform, and how to respond to this solicitation can be found at

About the Type 1 Diabetes PhysioLab Platform

The Entelos® Type 1 Diabetes PhysioLab® platform is a large-scale, mathematical model of the non-obese diabetic (NOD) mouse designed to support research in type 1 diabetes. The platform captures the physiology of pancreatic cell autoimmunity and tolerance from birth until disease onset. Virtual NOD mice are constructed using equations that mathematically represent cellular functions and biochemical interactions in tissues critical for the pathogenesis of type 1 diabetes. The model encompasses two main tissues: pancreatic lymph nodes (PLN) and pancreatic islets. Antigen and antigen-presenting cells traffic from the islets to the PLN, and conversely, lymphocytes activated in the PLN can enter the blood and be recruited to the islets. Functions at the biochemical and cellular levels are integrated and the dynamic relationships over time quantitatively linked via mathematical equations, making simulation and prediction of biological outcomes possible.

About the American Diabetes Association

The American Diabetes Association ( is the nation's premier voluntary health organization supporting diabetes research, information and advocacy. Founded in 1940, the Association has offices in every region of the country, providing services to hundreds of communities. The Association's commitment to research is reflected through its scientific meetings; education and provider recognition programs; and its Research Foundation and Nationwide Research Program, which fund breakthrough studies looking into the cure, prevention, and treatment of diabetes and its complications. For more information, please visit or call 1-800-DIABETES (1-800-342-2383). Information from both these sources is available in English and Spanish.

About Entelos

Entelos, Inc. ( is a US-based life sciences company building predictive in silico disease models and using "virtual patients" to revolutionize the way medicines are discovered, developed, and utilized. The Company's predictive computer models, known as PhysioLab® systems, are used to validate novel drug targets, select and develop compounds, assess safety, optimize clinical trials and combination therapies, reprofile drugs, evaluate in-licensing candidates, and better position existing products in competitive markets. In addition to internal programs, Entelos partners with global pharmaceutical and biotechnology companies and currently provides scientific expertise and models in such areas as cardiovascular disease, asthma, obesity, diabetes and rheumatoid arthritis, and complex physiological processes such as hematopoiesis (anemia), cholesterol metabolism, and skin sensitization.

Entelos is a registered trademark of Entelos, Inc. PhysioLab is a trademark and service mark of Entelos, Inc.

All other trademarks are the property of their registered owners.

Contact Information

  • Enquiries
    Entelos, Inc
    Jill Fujisaki
    Vice President, Investor Relations
    Tel: +1 650 572 5430
    Email Contact

    Diane Tuncer
    +1.703.549.1500 ext. 5510
    Email Contact

    Brunswick Group
    Justine McIlroy / Alex Tweed / Jon Coles
    Tel: +44 207404 5959